Xcout Intel
Avammune
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Subscribe to see Avammune’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Avammune at a glance
Avammune is a biotechnology company headquartered in India. Its most recent funding round, Series A, raised $12M in May 2025. Xcout tracks 5 named people at Avammune, including Aditya Kulkarni (Chief Scientific Officer).
Avammune leadership
- Aditya KulkarniChief Scientific Officer
- Arun B. PapaiahFounder | CEO
- Srinivasan NamalaFounder | Director
- Aditya KulkarniFounder | CSO
- Sandeep GoyalDirector | R&D
Avammune funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $12M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Avammune competitors
A few of Avammune's closest competitors — see the full list of competitors and alternatives →
Amphivena Therapeutics, Inc. is a privately held, clinical-stage biotechnology company based in South San Francisco, California. The company specializes in immuno-oncology, developing a platform of dual-function biologics and selective T cell engagers for the treatment of hematological conditions.
AbbraTech Holdings LLC operates a platform technology focused on recombinant antibody discovery, engineering, and validation. The company targets human diseases such as cancer, immune disorders, and viral infections by developing antibodies for difficult-to-reach drug targets through its proprietary Epivolve technology.
Inventisbio is a biopharmaceutical company that focuses on the discovery and development of innovative drugs for major diseases such as tumors, autoimmune diseases, and metabolic disorders. Utilizing an independent research and development platform, the company creates proprietary drug pipelines targeting oncology drivers, kinases, and autoimmune pathways to serve patients globally.
Immune Design Corp. is a clinical-stage immunotherapy company with offices in Seattle, Washington, and South San Francisco, California, specializing in novel drug discovery and treatment technologies.
RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.
Get Avammune's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Avammune in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access